The Evolution of Adjuvant Therapy in the Treatment of Early-Stage Colon Cancer

被引：20

作者：

de Gramont, Aimery ^{[1
,2
,3
]}

de Gramont, Armand ^{[1
]}

Chibaudel, Benoist ^{[1
]}

Larsen, Annette K. ^{[2
]}

Tournigand, Christophe ^{[1
,2
]}

Andre, Thierry ^{[1
,2
,3
]}

机构：

[1] Hop St Antoine, Med Oncol Serv, AP HP, F-75012 Paris, France

[2] INSERM, Unite Mixte Rech S 938, F-75654 Paris 13, France

[3] Univ Paris 06, Paris, France

来源：

CLINICAL COLORECTAL CANCER | 2011年 / 10卷 / 04期

关键词：

Adjuvant chemotherapy; Bevacizumab; Biomarkers; Cetuximab; Elderly; Fluoropyrimidines; Oxaliplatin; Phase III; Stage II colon cancer; Stage III colon cancer; METASTATIC COLORECTAL-CANCER; RANDOMIZED PHASE-III; INDIVIDUAL PATIENT DATA; DISEASE-FREE SURVIVAL; BOLUS FLUOROURACIL; PLUS IRINOTECAN; GENE-EXPRESSION; POOLED ANALYSIS; BREAST-CANCER; END-POINTS;

D O I：

10.1016/j.clcc.2011.10.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Adjuvant treatment of colon cancer, one of the most common malignancies, is an important issue in oncology. This article describes the development of adjuvant therapy and how the 2 major evolution steps, the successes of fluoropyrimidines, and then of oxaliplatin, have been achieved, Problems and failures, such as those of targeted therapies, also are addressed to help us to overcome their limitations. Special situations, such as stage II disease and an elderly population in which adjuvant chemotherapy is still controversial, are reviewed from the clinician perspective. The synthesis of these data allows us to conceive a future development focused on translational research. Clinical Colorectal Cancer, Vol. 10, No. 4, 218-26 (C) 2011 Elsevier Inc. All rights reserved.

引用

页码：218 / 226

页数：9

共 97 条

[1] Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial [J].

Albain, Kathy S. ;

Barlow, William E. ;

Ravdin, Peter M. ;

Farrar, William B. ;

Burton, Gary V. ;

Ketchel, Steven J. ;

Cobau, Charles D. ;

Levine, Ellis G. ;

Ingle, James N. ;

Pritchard, Kathleen I. ;

Lichter, Allen S. ;

Schneider, Daniel J. ;

Abeloff, Martin D. ;

Henderson, I. Craig ;

Muss, Hyman B. ;

Green, Stephanie J. ;

Lew, Danika ;

Livingston, Robert B. ;

Martino, Silvana ;

Osborne, C. Kent .

LANCET, 2009, 374 (9707) :2055-2063

[2]

Alberts SR, 2010, J CLIN ONCOL S18, V28, p959s

[3] Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08 [J].

Allegra, Carmen J. ;

Yothers, Greg ;

O'Connell, Michael J. ;

Sharif, Saima ;

Petrelli, Nicholas J. ;

Colangelo, Linda H. ;

Atkins, James N. ;

Seay, Thomas E. ;

Fehrenbacher, Louis ;

Goldberg, Richard M. ;

O'Reilly, Seamus ;

Chu, Luis ;

Azar, Catherine A. ;

Lopa, Samia ;

Wolmark, Norman .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (01) :11-16

[4] Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer [J].

Allegra, Carmen J. ;

Yothers, Greg ;

O'Connell, Michael J. ;

Sharif, Saima ;

Colangelo, Linda H. ;

Lopa, Samia H. ;

Petrelli, Nicholas J. ;

Goldberg, Richard M. ;

Atkins, James N. ;

Seay, Thomas E. ;

Fehrenbacher, Louis ;

O'Reilly, Seamus ;

Chu, Luis ;

Azar, Catherine A. ;

Wolmark, Norman .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) :3385-3390

[5]

Allegra CJ, 2011, J CLIN ONCOL S, V29

[6] Molecular mechanisms underlying tumor dormancy [J].

Almog, Nava .

CANCER LETTERS, 2010, 294 (02) :139-146

[7] Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy [J].

Amit, Ido ;

Wides, Ron ;

Yarden, Yosef .

MOLECULAR SYSTEMS BIOLOGY, 2007, 3 (1)

[8] Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].

Andre, T ;

Boni, C ;

Mounedji-Boudiaf, L ;

Navarro, M ;

Tabernero, J ;

Hickish, T ;

Topham, C ;

Zaninelli, M ;

Clingan, P ;

Bridgewater, J ;

Tabah-Fisch, I ;

de Gramont, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351

[9]

Andre T, 2011, J CLIN ONCOL, V29

[10] Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer:: Results of a randomized trial [J].

André, T ;

Colin, P ;

Louvet, C ;

Gamelin, E ;

Bouche, O ;

Achille, E ;

Colbert, N ;

Boaziz, C ;

Piedbois, P ;

Tubiana-Mathieu, N ;

Boutan-Laroze, A ;

Flesch, M ;

Buyse, M ;

de Gramont, A .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2896-2903

← 1 2 3 4 5 6 7 8 9 10 →